Navigation Links
Ardea Biosciences to Present at Two Upcoming Investor Conferences
Date:3/5/2010

for the treatment of gout, cancer and human immunodeficiency virus (HIV).  RDEA594, our lead product candidate in development for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development.  Our next-generation URAT1 inhibitor, RDEA684, is currently in preclinical development.  RDEA119, a potent and specific inhibitor of mitogen-activated ERK kinase (MEK), is being developed under a global license agreement with Bayer HealthCare AG.  RDEA119 is currently being evaluated in advanced cancer patients with different tumor types as a single agent in a Phase 1 study, as well as in combination with sorafenib (Nexavar®, Bayer HealthCare, Onyx Pharmaceuticals, Inc.) in a Phase 1/2 study.  RDEA806, for the treatment of HIV, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that has successfully completed a Phase 2a study in HIV patients.  RDEA427, a next generation NNRTI, has superior pharmacokinetic properties, and even greater activity against a wide range of drug-resistant viral isolates than RDEA806.  We have evaluated RDEA427 in a human micro-dose pharmacokinetic study.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of RDEA594, RDEA684, RDEA119, RDEA806, RDEA427 and our other compounds and the timing
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
2. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
3. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
4. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
5. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
6. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
7. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
8. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
11. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... membrane market has witnessed robust development with the growth pace ... later starter. In 2012, the size of China ... the proportion worldwide soaring to 16.3%. It is projected that ... its growth rate by around 20% in the upcoming years ... RMB25 billion. An integrated membrane industrial system has ...
(Date:12/17/2014)... 2014  Northstar Global Business Services, Inc. (OTCPink:MDIN) ... has made their final decision and has determined ... stock effective December 15, 2014, and has resumed ... and book entry transfer services. All deposit restrictions have ... again fully "DTC Eligible", and has resumed electronic ...
(Date:12/17/2014)... N.J. , Dec. 17, 2014  IGI Laboratories, ... today the closing of its offering of $125 million ... 2019 (the "Notes").  The Notes were offered and sold ... under the Securities Act of 1933, as amended (the ... a fixed rate of 3.75% per year, payable semiannually ...
Breaking Medicine Technology:Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... 16, 2011 PDL BioPharma, Inc. (PDL) (NASDAQ: ... 15, 2011, regular quarterly dividend payment of $0.15 per share to ... the record date. About PDL BioPharma ... by doing so, enabled the discovery of a new generation of ...
... 2011 The U.S. Food and Drug Administration today ... adult patients who have had a kidney transplant. ... immunosuppressants (medications that suppress the immune system) -- ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Nulojix is ...
Cached Medicine Technology:FDA Approves Nulojix for Kidney Transplant Patients 2FDA Approves Nulojix for Kidney Transplant Patients 3
(Date:12/21/2014)... (PRWEB) December 22, 2014 Weddingshe.com, an ... occasion gowns, has recently released its new selection of ... models are made according to the newest fashion trends. ... stunning dresses for cocktail parties . All of ... 80 percent off. We are making every effort to ...
(Date:12/21/2014)... December 21, 2014 Khanna Vision Institute ... guest at the Aspen Helicopters holiday event for underprivileged ... Santa with sleigh, flown by an aspen helicopter pilot. ... only Santa with sleigh was visible.(please see accompanying video). ... night. Dr.Khanna has helped many pilots with Pi in ...
(Date:12/21/2014)... AngelWeddingDress.com’s new collection of 2015 spring wedding dresses ... new designs in this collection, and all of them ... AngelWeddingDress.com promises to provide the most fashionable designs ... many fashion trends come and go. If ladies have ... AngelWeddingDress.com is ready to assist. , “These new ...
(Date:12/21/2014)... Dennis Thompson HealthDay Reporter ... smokers find e-cigarettes less addictive than traditional cigarettes, new research ... as they did regular cigarettes, thousands of ex-smokers said they ... and irritable over their need to smoke, researchers reported. ... was significantly less for e-cig use than for tobacco use," ...
(Date:12/21/2014)... 2014 The number of Mirena lawsuits ... litigation underway in New Jersey, Bernstein Liebhard LLP reports. ... claims involving the birth control IUD have now been ... filed by women who allege spontaneous migration of the ... perforations and other complications they were inadequately warned about ...
Breaking Medicine News(10 mins):Health News:Stunning Cocktail Party Dresses from Weddingshe.com 2Health News:2015 Spring Wedding Dresses From AngelWeddingDress Just Released 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3
... International Diabetes Federation (IDF) BRIDGES translational research grant ... seeks to reduce the risk of for people ... The community based diabetes prevention programme will determine ... research studies of lifestyle interventions for diabetes prevention ...
... YORK (May 29, 2008) -- Physician-scientists from NewYork-Presbyterian ... research findings at the American Society of Clinical ... June 3. Among the most significant presentations are ... OncoVEXGM-CSF for Patients With Unresectable Metastatic Melanoma , ...
... N.J., May 30 Lutronic, Inc., one of,the ... systems,announced today that its MOSAIC eCO2 system, the ... with the deep,ablative features of a CO2 laser, ... and,clearance., With intuitive touch-screen software, the powerful ...
... The world was stunned by the,news of ... 70,000 dead and,thousands more injured and homeless. In ... Wheelchair Mission (FWM), a non-profit,organization dedicated to transforming ... with Holistic Integrated Service Foundation (HIS),a nonprofit in ...
... Find New Video ,Milestones in Oncology, Presentations at ... The Society for Translational Oncology,(STO) is pleased to ... uniquely valuable video presentations for practicing,oncologists., (Logo: ... made on the occasion of the 2008 Annual ...
... with advanced cancer were more likely than whites to ... greater preference among blacks for life-extending treatment even in ... study led by researchers at Dana-Farber Cancer Institute in ... the annual meeting of the American Society of Clinical ...
Cached Medicine News:Health News:International Diabetes Federation grant supports study to prevent type 2 diabetes in India 2Health News:NYP/Columbia physician-scientists present at ASCO 44th annual meeting 2Health News:NYP/Columbia physician-scientists present at ASCO 44th annual meeting 3Health News:NYP/Columbia physician-scientists present at ASCO 44th annual meeting 4Health News:Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use 2Health News:Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use 3Health News:Free Wheelchair Mission to Distribute 4,400 Wheelchairs to China Earthquake Victims 2Health News:Society for Translational Oncology Launches Updated Website 2Health News:Black patients with terminal cancer more likely to choose aggressive care at end of life 2
... is the first truely web-based solution on the ... POC (managed from the lab) and Critical Care ... of AegisPOC ensures that all groups have the ... in the manner best suited to them. Through ...
... ultrasonic technology. When managing glaucoma patients and ... to use the best technology available. ... analog and digital technology that utilizes ultrasound ... other ultrasonic pachymeters in the market. This ...
...
...
Medicine Products: